[144] OCULAR THERAPEUTIX, INC SEC Filing
Rhea-AI Filing Summary
Ocular Therapeutix (OCUL) filing a Form 144 notifies the proposed sale of 10,502 common shares with an aggregate market value of $115,889.57. The shares were acquired on 10/01/2025 through restricted stock vesting under a registered plan, and the proposed approximate sale date is 10/02/2025 through Morgan Stanley Smith Barney LLC on NASDAQ. The filing reports 173,995,221 shares outstanding for the issuer. It also discloses a recent sale by the same person: 3,063 shares sold on 08/25/2025 for $36,882.81. The filer affirms they are not aware of any undisclosed material adverse information.
Positive
- 10,502 shares were acquired by restricted stock vesting under a registered plan (compensation-related origin)
- Filer affirms no knowledge of undisclosed material adverse information
Negative
- Proposed sale of 10,502 shares with aggregate market value $115,889.57
- Recent prior sale of 3,063 shares on 08/25/2025 for $36,882.81
Insights
TL;DR: Insider plans to sell 10,502 vested shares worth $115,889.57; prior sale of 3,063 shares noted.
The Form 144 shows an insider sale authorization for 10,502 common shares acquired by restricted stock vesting on 10/01/2025, with an approximate sale date of 10/02/2025 via Morgan Stanley Smith Barney LLC.
The filing also records a prior disposition of 3,063 shares on 08/25/2025 that generated $36,882.81 in gross proceeds. The issuer's reported outstanding share count is 173,995,221, which provides context for the scale of these transactions relative to total shares.